Theravance Biopharma, Inc. Common Stock, Capital Shares Reserved for Future Issuance
Theravance Biopharma, Inc. (TBPH) had Common Stock, Capital Shares Reserved for Future Issuance of 7.03 million shares as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-03-23
- 2025-12-31: Common Stock, Capital Shares Reserved for Future Issuance 7.03M shares.
- 2024-12-31: Common Stock, Capital Shares Reserved for Future Issuance 7.87M shares.
- 2023-12-31: Common Stock, Capital Shares Reserved for Future Issuance 8.14M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2025-12-31 | 7.03M shares 10-K · filed 2026-03-23 |
| 2024-12-31 | 7.87M shares 10-K · filed 2025-03-07 |
| 2023-12-31 | 8.14M shares 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |